



Cameroon COVID-19 Preparedness and Response Project (P174108)

WESTERN AND CENTRAL AFRICA | Cameroon | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2021 | Seq No: 4 | ARCHIVED on 25-Jul-2022 | ISR51995 |

Implementing Agencies: Ministry of Public Health, Republic of Cameroon

Key Dates

Key Project Dates

Bank Approval Date: 22-Sep-2020

Effectiveness Date: 17-Sep-2021

Planned Mid Term Review Date: 22-May-2023

Actual Mid-Term Review Date:

Original Closing Date: 30-Jun-2022

Revised Closing Date: 30-Jun-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in selected regions in Cameroon.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name
Emergency COVID-19 Response:(Cost \$63.10 M)
Supporting National and Sub-National Prevention and Preparedness:(Cost \$2.00 M)
Community Engagement and Risk Communication:(Cost \$3.00 M)
Implementation Management and Monitoring & Evaluation:(Cost \$5.50 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Moderately Unsatisfactory	<input type="checkbox"/> Moderately Unsatisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Unsatisfactory	<input type="checkbox"/> Moderately Unsatisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> High

Implementation Status and Key Decisions

The project was approved on September 22, 2020, in the amount of US\$29 million to address urgent response needs to COVID-19 pandemic and became effective on September 17, 2021. An additional financing to support purchasing and deployment of COVID-19 vaccines and to support the continuity of essential health services related to maternal and child health, that have been negatively impacted by the pandemic, was approved on December 23, 2021, increasing the project envelope by US\$44.6 million (IDA: US\$29.6 million; Global Financing Facility grant: US\$15 million) for a total of \$73.6 million. It is expected that the project will support the vaccination of about 20% of the population and mitigate the cyclical negative effect of the maternal and child health service provision decrease related to pandemic peaks.



MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of July 15, 2022, 88 MPA-projects had been approved with a total commitment of US\$4.3 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Six parent projects have been restructured to include vaccine-related procurement. Total disbursements as of July 15, 2022, amount to US\$3.64 billion or 85% of overall commitments. This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. Sixty-seven (67) country projects or 77% of projects approved have reached 70-100% disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). Out of the 67 operations, 48 operations or 72% have disbursed over 90% of commitments. Of these, 30 operations are fully disbursed. There were only three (3) operations with closing dates by the end of FY22. Other 16 operations which had closing dates by the end of FY22 have extended their closing dates. There are 11 operations with disbursements under 50%. Out of these 11 operations, one has not disbursed, and four have disbursed 30 percent or less. The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 87 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 8 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-six (86) or 99% of projects approved are disbursing. MNA has the highest percentage of disbursements, followed by SRA, EAP, ECA, LAC, AFE and AFW. Retroactive Financing represents 26% of commitments. Country teams for operations, which have been under implementation for twelve months or more by June 30, 2022, have prepared and/or finalizing Mid-Term Review (MTR) ISRs to inform the Global MPA MTR, which will be prepared by the EOC early next FY.

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of mobility restrictions. Bank staff are operating in a hybrid environment with some days at the office and others at home. Virtual missions have continued to be the norm in some countries. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach ("Global COVID-19 MPA") was approved by the Board on October 13, 2021. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion. This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG's overall COVID-19 response.



As of July 15, 2022, the Bank has approved 115 operations (including MPA-V operations) to support vaccine procurement and rollout in 78 countries amounting to \$10.1 billion. The 115 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 115 approved operations: (i) 64 are in Africa – 29 in AFE and 35 in AFW; (ii) 9 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 13 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Thirty-four (34) operations have been approved so far this Calendar Year. Fifty-nine (59) projects are disbursing. Total disbursements as of July 15, 2022, under these projects amount to US\$3.98 billion or 40% of overall commitments. Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. Twenty-one (21) operations have disbursed over 70% of their commitments. Out of the 21, nine have disbursed 90%. Retroactive Financing (RF) represents 39% of overall commitments. High RF has been authorized under different operations Indonesia and Ukraine (100%), Panama and Turkey (90%), Argentina and Guyana (80%), and Belize, Iraq and Sri Lanka (70%). Three (3) new operations are under various stages of processing. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Ninety-seven (97) loan/financing agreements have been signed. Also, eighty-seven (87) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of mobility restrictions and counterparts and Bank teams are operating in a hybrid environment with some days at the office and some at home. Virtual missions have continued to be the norm in some countries. Countries are continuing to deal with sharp increases of infections, as the Omicron variant continues to spread rapidly among populations. The omicron variant spread rapidly across the world, out-competing former variants soon after it was first detected in November 2021.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	Substantial	Substantial	Substantial
Macroeconomic	Substantial	Substantial	Substantial
Sector Strategies and Policies	Moderate	Moderate	Moderate
Technical Design of Project or Program	Substantial	Moderate	Moderate
Institutional Capacity for Implementation and Sustainability	Substantial	High	High
Fiduciary	Substantial	Substantial	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	Substantial	Substantial	Substantial
Other	Substantial	Substantial	Substantial
Overall	Substantial	High	High

Results

PDO Indicators by Objectives / Outcomes



To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems				
▶ Priority population vaccinated against COVID-19, based on targets defined in the national plan (proportion of females) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	5.70	5.70	5.70	40.00
Date	30-Nov-2021	30-Nov-2021	27-May-2022	30-Jun-2024
□ Females (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	36.00	36.00	36.00	49.00
Date	30-Nov-2021	30-Nov-2021	27-May-2022	30-Jun-2024
▶ Designated laboratories supported with personnel, equipment, test kits and reagents (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	16.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024
▶ Births assisted by skilled health personnel in the 3 Northern regions (Adamawa, North, Extreme North) and East region (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	178,282.00	178,282.00	178,282.00	285,600.00
Date	30-Dec-2020	30-Dec-2020	27-May-2022	30-Jun-2024

Intermediate Results Indicators by Components

Emergency COVID-19 Response				
▶ Health facilities with a COVID-19 case management unit (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	91.00	91.00	91.00	200.00
Date	10-Nov-2021	10-Nov-2020	27-May-2022	30-Jun-2024
▶ Health staff trained in COVID-19 vaccination deployment (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target



Value	4,548.00	4,548.00	4,548.00	9,000.00
Date	30-Nov-2021	30-Nov-2021	27-May-2022	30-Jun-2024
<input type="checkbox"/> Female health staff trained in COVID-19 vaccination (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	2,106.00	2,106.00	2,106.00	4,400.00
Date	30-Nov-2021	30-Nov-2021	27-May-2022	30-Jun-2024
<input type="checkbox"/> Doses of eligible COVID-19 vaccines procured (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	3,500,000.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Supporting National and Sub-national, Prevention and Preparedness

Laboratories awarded with 3 stars or above based on the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) audits (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	16.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Community Engagement and Risk-Communication

Radio stations and TV channels broadcasting COVID-19 vaccination information in official and local languages (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	147.00	147.00	147.00	300.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Grievances addressed according to the project's GRM timeframe and procedures (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	80.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Community health workers trained to delivery key messages to promote demand for COVID-19 vaccines and other essential health services (Number, Custom)



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	25.00	25.00	25.00	75.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024
□ Female community health workers (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	49.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Implementation Management and Monitoring and Evaluation

► Routine monitoring of essential health services regional reports reviewed quarterly by the MoPH (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	36.00
Date	10-Nov-2021	10-Nov-2021	27-May-2022	30-Jun-2024

Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P174108	IDA-67830	Effective	USD	29.00	29.00	0.00	0.00	27.21	0%
P174108	IDA-70320	Not Effective	USD	29.60	29.60	0.00	0.00	29.56	0%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P174108	IDA-67830	Effective	22-Sep-2020	20-Aug-2021	17-Sep-2021	30-Jun-2022	30-Jun-2024
P174108	IDA-70320	Not Effective	23-Dec-2021	--	--	30-Jun-2024	30-Jun-2024

Cumulative Disbursements



Restructuring History

There has been no restructuring to date.

Related Project(s)

P178255-Additional Financing for Cameroon COVID-19 Preparedness and Response Project